Phase 4 N=59 Immediate vs. Delayed Postpartum Etonogestrel Implant
Continuation Rate of Contraceptive Implant
Primary: Continuation Rate — 20; 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=66 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Cancer
Primary: NRS (Numeric Rating Scale) — -1.29 units on a scale
Phase 4 N=23 Concentration of Ertapenem in Colorectal Tissue
Diverticulosis, Colonic · Rectal Neoplasms · Colonic Neoplasms
Primary: Concentration of Ertapenem in Colorectal Tissue in mg/kg 3 to 6 Hours After a Single Dose of 1 Gram Ertapenem I.V..
Phase 4 N=35 Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
Depression
Primary: Depressive Symptoms — 12.5; 13.4; 7; 5.2 units on a scale — p=0.42
Phase 4 N=146 Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline — -0.97; 0.13 Percent — p=<0.001
Phase 4 N=141 Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score at Day 14 — 2.70; 2.74; -1.38; -0.10 score on a scale — p=<0.0001
Phase 4 N=75 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
Pancreatic Cancer · Venous Thromboembolism
Primary: Number of Participants With Venous Thromboembolic Events (VTE) — 2; 9 participants
Phase 4 N=208 Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
Influenza
Primary: Number of Participants With Solicited Injection-Site or Systemic Reactions After Receipt of the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal…
Phase 4 N=24 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects
Primary Immune Deficiency Disease
Primary: Serious Bacterial Infections. — 1; 0 Total serious bacterial infections
Phase 4 N=366 A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
Coronary Artery Disease · Heart Disease
Primary: Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up — 2; 1; 1; 5…
Phase 4 N=201 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
Open-Angle Glaucoma · Ocular Hypertension
Primary: Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM — 17.0; 17.0; -3.3; -3.4 mmHg
Phase 4 N=50 Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
Encephalitis
Primary: Change From Baseline in Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination — 9144 titers
Phase 4 N=82 Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Bacteremia
Primary: Number of Participants With One or More Adverse Events (AEs) — 15; 6; 12; 9 Participants
Phase 4 N=12 Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
Obesity
Primary: Single-dose Serum AUC of Tigecycline Between Time 0 and 96 Hours — 7.64 hour*mg/L
Phase 4 N=1,001 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Multiple Sclerosis
Primary: Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 - Assessment of Global Satisfaction Subscale Score With Teriflunomide Treatment at Week 48 — 68.17…